Our Pipeline

AI Development

Advancing Toward Immediate Precision for Optimal Care

HRD detection is just our first step toward transforming precision medicine. Homologous Recombination Deficiency (HRD) is a notoriously challenging biomarker for traditional next-generation sequencing (NGS) methods. It often requires substantial tissue samples, suffers from high QNS (Quantity Not Sufficient) rates, and results in frequent delays, inconclusive outcomes, or ambiguous “gray zone” findings. 

Given HRD’s critical role in guiding treatment decisions for high-mortality cancers—such as pancreatic, ovarian, and advanced breast—starting here was a clear and urgent choice. 

But this is only the beginning. 

Our technology unlocks a new era of real-time, tissue-sparing biomarker detection. Beyond HRD, we’re rapidly expanding to other key biomarkers, across a broader range of cancers, and across the clinical care continuum. The same platform holds promise for accelerating clinical trial enrollment, optimizing study design, and driving smarter, faster drug development. 

We’re building more than a tool—we’re building the future of precision medicine. And that future is coming fast. 

Genomics that inform drug development

AI architecture for
predicting cancer
biomarkers
Initial biomarker: HRD ovarian and pancreatic cancer; breast cancer Future biomarkers: KRAS, EGFR, BRCA 1/2, HR gene panel, MMRD/MSI, mutational signatures*, various cancers
9p Loss Test for HPV
negative head
and neck cancers

Collaboration and Commercialization agreement with leading Oncology with CLIA lab

Mapping hot spot
mutations

Future Development and/or Partnership

Let's move cancer care forward – together.

Explore how Acurion is driving immediate precision for optimal care.
Contact us for a demo of OncoGaze™.